With the wide availability of generic opioid analgesics, such as oxycodone and hydromorphone, the abuse of prescription opioids has become a major public health problem in the US. Consequently, in January 2013, the FDA released draft guidance for drug makers that mandates inclusion of abuse-deterrent technology for new opioid products. Data from Pharmaprojects and Trialtrove were analyzed to explore the current development for opioid analgesics with abuse-deterrent technology in order to gain insight into the front runners of this competitive area, their characteristics, and the top sponsors on the verge of becoming market leaders.
One of the most common approaches in abuse-deterrent technology is the development of new formulations of extended-release opioids, or tamper resistant properties that render the drugs difficult to crush, grind, and dissolve for injection or nasal insufflation by potential abusers.
Find out more. Download whitepaper below.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: